EC Number   |
Application |
Reference |
|---|
   2.4.2.12 | drug development |
inhibitor-soaking experiments |
690246 |
| 2.4.2.12 | medicine |
a dose of 75 mg/kg GMX1777, i.e. 1-[2-(2-(2-(2-methoxyethoxy)-ethoxy)ethoxy)-ethoxy-carbonyloxymethyl]-4-[N'-cyano-N''-(6-(4-chlorophenyl)-hexyl)-N-guanidino]pyridinium chloride, prodrug of GMX1778, administered over a 24 h intravenous infusion causes tumor regression in the IM-9 model, the SHP-77 model, and HCT-116 model. A 72 h continuous intravenous infusion is also effective in the IM-9 model, but is associated with smaller therapeutic index |
701720 |
| 2.4.2.12 | medicine |
a dose of 75 mg/kg GMX1777, i.e. 1-[2-(2-(2-(2-methoxyethoxy)-ethoxy)ethoxy)-ethoxy-carbonyloxymethyl]-4-[N'-cyano-N''-(6-(4-chlorophenyl)-hexyl)-N-guanidino]pyridinium chloride, prodrug of GMX1778, administered over a 24 h intravenous infusion produces GMX1778 steady-state plasma levels of about 1 microg/ml and causes nicotinamide dinucleotide levels to decrease significnantly in tumors. Nicotinic acid protects mice treated with a lethal dose of GMX1777 |
701720 |
| 2.4.2.12 | medicine |
longevity enzyme for human SMCs |
680749 |
| 2.4.2.12 | medicine |
specific inhibition of enzyme transport into the nucleus might be a potential avenue for managing cancer |
759503 |
| 2.4.2.12 | medicine |
the enzyme is a therapeutic target in metastatic melanoma |
760200 |
| 2.4.2.12 | pharmacology |
enzyme is a potential target for development of anticancer drugs |
661421 |
| 2.4.2.12 | pharmacology |
NAMPT inhibition might have therapeutic efficacy in immune-mediated inflammatory diseases through impact on inflammatory cytokine secretion by leukocytes |
694813 |
